Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental hepatitis C treatment news

Show

From To
Gilead offers Egypt new hepatitis C drug at 99 percent discount

Gilead Sciences, facing mounting criticism over the high price of its new hepatitis C pill Sovaldi, has offered to supply the medicine to Egypt at a 99 percent discount to the U.S. price. While the drug will still cost $900 for a 12-week course of treatment, that is a fraction of the $84,000 charged for a course of treatment in the United States.

Published
24 March 2014
From
Reuters
US Lawmakers Attack Cost of New Hepatitis Drug

A new drug to treat hepatitis C that costs $1,000 a pill has caused rising concern among insurers and state Medicaid programs. It has now also spurred interest from Democratic congressmen whose queries about the drug prompted a sell-off in biotechnology stocks on Friday.

Published
24 March 2014
From
New York Times
Merck combination suppresses HCV in mono-infected and co-infected patients

An all-oral combination of the hepatitis C virus (HCV) protease inhibitor MK-5172 and NS5A inhibitor MK-8742, with or without ribavirin, demonstrated promising end-of-treatment viral suppression in people

Published
21 March 2014
By
Liz Highleyman
Trouble Ahead for Gilead and Sovaldi?

Atop ever-inflating sales estimates for Gilead Science's blockbuster Sovaldi, patent battles also continue to crop up. Late last week Idenix Pharmaceuticals added three more suits to the pile, filing in France, Germany and the UK for patent infringement on nucleosides, a precursor to the compound in Sovaldi. This is in addition to two lawsuits it has pending against Gilead stateside since late last year.

Published
19 March 2014
From
Motley Fool
How Much Should Hepatitis C Treatment Cost?

A new pill to treat hepatitis C raises difficult questions about fair pricing, not only in the United States and other affluent nations but in developing countries around the world.

Published
18 March 2014
From
New York Times (editorial)
Hepatitis C treatments: Australia urged to subsidise 'revolutionary' new drugs

Public health experts say effective new drugs to treat hepatitis C should be subsidised in Australia to avert a looming strain on the national health system.

Published
18 March 2014
From
ABC Online
Daclatasvir plus simeprevir are effective against hepatitis C genotype 1b

An all-oral regimen of daclatasvir plus simeprevir, without interferon or ribavirin, led to sustained response in 85 to 95% of people with hepatitis C genotype 1b, but

Published
13 March 2014
By
Liz Highleyman
Price of new hepatitis C drug questioned by U.S. medical experts

A panel of California medical experts voted Monday that Gilead's Sovaldi represents a "low value" treatment, considering its cost compared with older drugs for the blood-borne virus.

Published
12 March 2014
From
CBC News
New Treatments for Hepatitis C

A summary of the key hepatitis C studies at the 21st Conference on Retroviruses and Opportunistic Infections in Boston.

Published
10 March 2014
From
BETA blog
Global community-based networks unite to demand pharmaceuticals lower the price of hepatitis C treatment

The Global Network of People Living with HIV (GNP+), the International Network of People who Use Drugs (INPUD), the Global Forum on MSM and HIV (MSMGF) and the International Treatment Preparedness Coalition (ITPC) are gravely concerned that exorbitant prices for life-saving hepatitis C treatment will continue to result in unnecessary deaths, including among key populations and people living with HIV.

Published
10 March 2014
From
GNP+

Filter by country